BR9908886A - Gene codificando um marcador para câncer - Google Patents

Gene codificando um marcador para câncer

Info

Publication number
BR9908886A
BR9908886A BR9908886-0A BR9908886A BR9908886A BR 9908886 A BR9908886 A BR 9908886A BR 9908886 A BR9908886 A BR 9908886A BR 9908886 A BR9908886 A BR 9908886A
Authority
BR
Brazil
Prior art keywords
lab
cancers
cancer
protein
treatments
Prior art date
Application number
BR9908886-0A
Other languages
English (en)
Portuguese (pt)
Inventor
James A Radosevich
Original Assignee
James A Radosevich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by James A Radosevich filed Critical James A Radosevich
Publication of BR9908886A publication Critical patent/BR9908886A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR9908886-0A 1998-03-17 1999-03-11 Gene codificando um marcador para câncer BR9908886A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/040,485 US6166176A (en) 1998-03-17 1998-03-17 Cancer marker protein and peptides thereof
PCT/US1999/005365 WO1999047683A1 (en) 1998-03-17 1999-03-11 Gene encoding labyrinthin, a marker for cancer

Publications (1)

Publication Number Publication Date
BR9908886A true BR9908886A (pt) 2000-11-21

Family

ID=21911225

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9908886-0A BR9908886A (pt) 1998-03-17 1999-03-11 Gene codificando um marcador para câncer

Country Status (14)

Country Link
US (7) US6166176A (enExample)
EP (1) EP1062346B1 (enExample)
JP (2) JP2002512005A (enExample)
CN (2) CN101260401A (enExample)
AP (1) AP2000001917A0 (enExample)
AT (1) ATE337400T1 (enExample)
AU (2) AU762758B2 (enExample)
BR (1) BR9908886A (enExample)
CA (1) CA2323494A1 (enExample)
DE (1) DE69932926T2 (enExample)
EA (1) EA003735B1 (enExample)
IL (1) IL138208A0 (enExample)
OA (1) OA11487A (enExample)
WO (1) WO1999047683A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166176A (en) * 1998-03-17 2000-12-26 Immvarx, Inc. Cancer marker protein and peptides thereof
US20030031670A1 (en) * 1999-11-08 2003-02-13 Jack R. Wands Diagnosis and treatment of malignant neoplasms
US20050123545A1 (en) * 1999-11-08 2005-06-09 Wands Jack R. Diagnosis and treatment of malignant neoplasms
US6835370B2 (en) * 1999-11-08 2004-12-28 Rhode Island Hospital Diagnosis and treatment of malignant neoplasms
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
US7306919B1 (en) 2001-10-31 2007-12-11 Thornthwaite Jerry T Antigen-antibody cancer recognition system
CA2491017A1 (en) * 2002-07-03 2004-01-15 Immunogen, Inc. Antibodies to non-shed muc1 and muc16, and uses thereof
ES2318077T3 (es) * 2003-09-04 2009-05-01 Biomay Ag Polipeptidos hipoalergenicos basados en parvalbumina de peces.
AU2004291910A1 (en) * 2003-11-14 2005-06-02 Massachusetts Institute Of Technology Anti-hydroxylase antibodies and uses thereof
CN100457922C (zh) * 2005-10-20 2009-02-04 康哲医药研究(深圳)有限公司 检测酪丝亮肽抗肝癌效果的方法及所用试剂盒与基因芯片
RU2340896C1 (ru) * 2007-05-17 2008-12-10 Негосударственное научно-исследовательское учреждение "Биомедицинский центр" Способ диагностики онкологических заболеваний
GB201002627D0 (en) 2010-02-16 2010-03-31 Loxbridge Res Llp Aptamer based analyte detection method
MX2021007074A (es) * 2018-12-13 2021-10-13 Labyrx Immunologic Therapeutics Usa Ltd Péptidos basados en laberintina para inmunoterapias contra el cáncer y su uso.
EP3908612A4 (en) * 2019-01-08 2023-01-18 Labyrx Immunologic Therapeutics (USA) Limited CONSTRUCTS DIRECTED AT THE LABYRINTHIN OR A PART OF IT AND THEIR USES

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816402A (en) * 1986-01-07 1989-03-28 Northwestern University Murine hybridoma and diagnostic antibody produced thereby
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5223604A (en) * 1991-06-25 1993-06-29 S.P.I. Synthetic Peptides Incorporated Pseudomonas exoenzyme s peptide composition and method
US5728819A (en) * 1996-08-02 1998-03-17 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US5994062A (en) 1995-10-02 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Epithelial protein and DNA thereof for use in early cancer detection
US6166176A (en) 1998-03-17 2000-12-26 Immvarx, Inc. Cancer marker protein and peptides thereof
US6344548B1 (en) * 1998-06-24 2002-02-05 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US7135617B2 (en) * 1998-07-02 2006-11-14 Calgene Llc Diacylglycerol acyl transferase proteins
US6100077A (en) * 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
US7045326B2 (en) * 2001-02-23 2006-05-16 The Regents Of The University Of California Mono- and diacylglycerol acyltransferases and methods of use thereof
US20030161831A1 (en) * 2001-02-23 2003-08-28 Sylvaine Cases Mono-and diacylglycerol acyltransferases and methods of use thereof
MXPA05001239A (es) * 2002-07-31 2005-06-08 Monsanto Technology Llc Secuencias de acidos nucleicos de diacilglicerol aciltransferasa y productos asociados.
US8685679B2 (en) * 2004-11-04 2014-04-01 E I Du Pont De Nemours And Company Acyltransferase regulation to increase the percent of polyunsaturated fatty acids in total lipids and oils of oleaginous organisms
WO2010088426A1 (en) * 2009-01-31 2010-08-05 Board Of Regents, The University Of Texas System Engineering lipids in vegetative tissues of plants
ES2640100T3 (es) * 2010-06-28 2017-10-31 Commonwealth Scientific And Industrial Research Organisation Métodos para producir lípidos

Also Published As

Publication number Publication date
CA2323494A1 (en) 1999-09-23
AU2999699A (en) 1999-10-11
JP2002512005A (ja) 2002-04-23
US8163883B2 (en) 2012-04-24
US20100112582A1 (en) 2010-05-06
US7329743B2 (en) 2008-02-12
US6166176A (en) 2000-12-26
AU2003204331B2 (en) 2008-02-07
US20050208508A1 (en) 2005-09-22
US7635759B2 (en) 2009-12-22
US6727080B1 (en) 2004-04-27
US20080249284A1 (en) 2008-10-09
US20100233711A1 (en) 2010-09-16
WO1999047683A1 (en) 1999-09-23
EP1062346A1 (en) 2000-12-27
CN101260401A (zh) 2008-09-10
CN100372938C (zh) 2008-03-05
AP2000001917A0 (en) 2000-09-30
EP1062346B1 (en) 2006-08-23
CN1301302A (zh) 2001-06-27
DE69932926T2 (de) 2007-05-24
OA11487A (en) 2004-05-04
EA003735B1 (ru) 2003-08-28
HK1033151A1 (en) 2001-08-17
JP2009165492A (ja) 2009-07-30
DE69932926D1 (de) 2006-10-05
WO1999047683A9 (en) 1999-11-18
ATE337400T1 (de) 2006-09-15
EA200000845A1 (ru) 2001-08-27
IL138208A0 (en) 2001-10-31
US20110110963A1 (en) 2011-05-12
AU762758B2 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
Kawakami et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
Guerra et al. Hereditary palmoplantar keratodermas. Part I. Non‐syndromic palmoplantar keratodermas: classification, clinical and genetic features
Hirakata et al. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease
HUP0500345A2 (hu) Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására
BR0012069A (pt) Composições e métodos para a terapia e diagnóstico de câncer pulmonar
US11268127B2 (en) Systems and devices for protease detection based on engineered polymers and biopolymers and methods of use
Damaj et al. Physical association of Gi2α with interleukin-8 receptors
Maddy et al. Epidermal growth factor receptors in human prostate cancer: correlation with histological differentiation of the tumour
BR9912007A (pt) Composições e métodos para terapia e diagnóstico de câncer de próstata
BR0009537A (pt) Composições para tratamento e diagnóstico de câncer de mama e métodos para seu uso
HUP0102257A2 (hu) Módosított K-vitamin-dependens polipeptidek
AP2000001917A0 (en) Gene encoding labyrinthin, a marker for cancer.
BR0112602A (pt) Compostos e métodos para tratamento e diagnóstico de infecção clamidial
BR9712518A (pt) Polipeptìdeo, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica, vacina, proteìna de fusão, processo para detectar tuberculose em um paciente, e, kit diagnóstico
BRPI0417023A (pt) anticorpo ou fragmento de anticorpo humanos, uso dos mesmos, composição farmacêutica, métodos para tratar um paciente que sofre de um distúrbio amilóide, para diagnosticar um distúrbio amilóide em um paciente, e para detectar a presença do apoe-ctd em uma amostra de um paciente, polinucleotìdeo, vetor, célula hospedeira, vìrus, e, kit para detectar apoe-ctd
BR9916020A (pt) Compostos e métodos para o tratamento e diagnóstico de infecção por chlamydia
Buxbaum et al. Alpha and gamma heavy chain diseases in man: intracellular origin of the aberrant polypeptides
AU2023201072B2 (en) Compositions and methods for diagnosing lyme disease and for predicting lyme disease spirochete elimination after treatment
BR0113213A (pt) Método para diagnosticar uma doença auto-imune, anticorpo, composição de diagnóstico, e, uso do anticorpo
BR112023015191A2 (pt) Agentes terapêuticos e de diagnóstico e usos dos mesmos
BR9510067A (pt) Peptídio capaz de interagir com o domínio sh3 da proteína gap anticorpo ou fragmento de anticorpo dirigido contra um polipeptídeo sequência nucleotídica codificando para um polipeptídio ácido nucléico anti-sentido capaz de inibir ao menos parcialmente a produção de polipeptídeos sua utilização composição farmacêutica e utilização de um anticorpo ou fragmento de anticorpo
Zhang et al. Proteomic and N‐glycoproteomic quantification reveal aberrant changes in the human saliva of oral ulcer patients
BR9914892A (pt) Composição farmacêutica, contendo fragmentos de um dna de codificação de proteìna antigênica dotado com efeito antitumor
MXPA02009791A (es) El gen de alta masa osea de 11q13.3.
CN101466831A (zh) 用于诊断和治疗利什曼病的化合物和方法

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: IMMVARX, INC. (US)

B25G Requested change of headquarter approved

Owner name: IMMVARX, INC. (US)

Free format text: ALTERADA A SEDE DO TITULAR CONFORME SOLICITADO NA PETICAO NO 008449/RJ DE 16/02/2004.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 11, 13, 10 (IX), 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.